| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| January 6th, 2006 | 26 | No |
Popular Name: L-783277 L-783277
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 1.53 | 2.55 | -11.63 | 3 | 7 | 0 | 113 | 364.394 | 1 | ↓ |
| Hi High (pH 8-9.5) | 1.53 | 3.55 | -52.89 | 2 | 7 | -1 | 116 | 363.386 | 1 | ↓ |
| Hi High (pH 8-9.5) | 1.53 | 3.38 | -51.25 | 2 | 7 | -1 | 116 | 363.386 | 1 | ↓ |
| Hi High (pH 8-9.5) | 1.53 | 2.51 | -53.76 | 2 | 7 | -1 | 116 | 363.386 | 1 | ↓ |
| Hi High (pH 8-9.5) | 1.53 | 4.47 | -53.61 | 2 | 7 | -1 | 116 | 363.386 | 1 | ↓ |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| ALK-1-E | ALK Tyrosine Kinase Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 763 | 0.33 | Binding ≤ 10μM |
| KIT-1-E | Stem Cell Growth Factor Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 303 | 0.35 | Binding ≤ 10μM |
| LCK-3-E | Tyrosine-protein Kinase LCK (cluster #3 Of 4), Eukaryotic | Eukaryotes | 750 | 0.33 | Binding ≤ 10μM |
| MAPK5-1-E | MAP Kinase-activated Protein Kinase 5 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 640 | 0.33 | Binding ≤ 10μM |
| MK01-1-E | Mitogen-activated Protein Kinase 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 950 | 0.32 | Binding ≤ 10μM |
| MP2K2-1-E | Dual Specificity Mitogen-activated Protein Kinase Kinase 2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 15 | 0.42 | Binding ≤ 10μM |
| TYK2-1-E | Tyrosine-protein Kinase TYK2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 4100 | 0.29 | Binding ≤ 10μM |
| VGFR2-1-E | Vascular Endothelial Growth Factor Receptor 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 57 | 0.39 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| ALK_HUMAN | Q9UM73 | ALK Tyrosine Kinase Receptor, Human | 763 | 0.33 | Binding ≤ 1μM |
| MP2K2_HUMAN | P36507 | Dual Specificity Mitogen-activated Protein Kinase Kinase 2, Human | 15 | 0.42 | Binding ≤ 1μM |
| MK01_HUMAN | P28482 | MAP Kinase ERK2, Human | 950 | 0.32 | Binding ≤ 1μM |
| MAPK5_HUMAN | Q8IW41 | MAP Kinase-activated Protein Kinase 5, Human | 640 | 0.33 | Binding ≤ 1μM |
| KIT_HUMAN | P10721 | Stem Cell Growth Factor Receptor, Human | 303 | 0.35 | Binding ≤ 1μM |
| LCK_HUMAN | P06239 | Tyrosine-protein Kinase LCK, Human | 750 | 0.33 | Binding ≤ 1μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 2 | 0.47 | Binding ≤ 1μM |
| ALK_HUMAN | Q9UM73 | ALK Tyrosine Kinase Receptor, Human | 763 | 0.33 | Binding ≤ 10μM |
| MP2K2_HUMAN | P36507 | Dual Specificity Mitogen-activated Protein Kinase Kinase 2, Human | 15 | 0.42 | Binding ≤ 10μM |
| MK01_HUMAN | P28482 | MAP Kinase ERK2, Human | 950 | 0.32 | Binding ≤ 10μM |
| MAPK5_HUMAN | Q8IW41 | MAP Kinase-activated Protein Kinase 5, Human | 640 | 0.33 | Binding ≤ 10μM |
| KIT_HUMAN | P10721 | Stem Cell Growth Factor Receptor, Human | 303 | 0.35 | Binding ≤ 10μM |
| LCK_HUMAN | P06239 | Tyrosine-protein Kinase LCK, Human | 6200 | 0.28 | Binding ≤ 10μM |
| TYK2_HUMAN | P29597 | Tyrosine-protein Kinase TYK2, Human | 4100 | 0.29 | Binding ≤ 10μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 2 | 0.47 | Binding ≤ 10μM |
| Description | Species |
|---|---|
| Activation of the AP-1 family of transcription factors | |
| Advanced glycosylation endproduct receptor signaling | |
| CD28 co-stimulation | |
| CD28 dependent PI3K/Akt signaling | |
| CD28 dependent Vav1 pathway | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| CREB phosphorylation through the activation of Ras | |
| CTLA4 inhibitory signaling | |
| DAP12 signaling | |
| Downstream TCR signaling | |
| EPHA-mediated growth cone collapse | |
| ERK/MAPK targets | |
| ERK2 activation | |
| ERKs are inactivated | |
| FCERI mediated MAPK activation | |
| Gastrin-CREB signalling pathway via PKC and MAPK | |
| Generation of second messenger molecules | |
| Golgi Cisternae Pericentriolar Stack Reorganization | |
| GPVI-mediated activation cascade | |
| Growth hormone receptor signaling | |
| Integrin cell surface interactions | |
| Interferon alpha/beta signaling | |
| Interleukin-2 signaling | |
| Interleukin-6 signaling | |
| MEK activation | |
| NCAM signaling for neurite out-growth | |
| Nef and signal transduction | |
| Nef Mediated CD4 Down-regulation | |
| Negative regulation of FGFR signaling | |
| Neurophilin interactions with VEGF and VEGFR | |
| Oncogene Induced Senescence | |
| Oxidative Stress Induced Senescence | |
| PD-1 signaling | |
| PECAM1 interactions | |
| phospho-PLA2 pathway | |
| Phosphorylation of CD3 and TCR zeta chains | |
| PIP3 activates AKT signaling | |
| RAF phosphorylates MEK | |
| Recycling pathway of L1 | |
| Regulation of actin dynamics for phagocytic cup formation | |
| Regulation of HSF1-mediated heat shock response | |
| Regulation of IFNA signaling | |
| Regulation of KIT signaling | |
| RSK activation | |
| Senescence-Associated Secretory Phenotype (SASP) | |
| Signal attenuation | |
| Signal transduction by L1 | |
| Signaling by FGFR | |
| Signaling by SCF-KIT | |
| Thrombin signalling through proteinase activated receptors (PARs) | |
| Translocation of ZAP-70 to Immunological synapse | |
| Uptake and function of anthrax toxins | |
| VEGF binds to VEGFR leading to receptor dimerization | |
| VEGFA-VEGFR2 Pathway | |
| VEGFR2 mediated cell proliferation |
No pre-computed analogs available. Try a structural similarity search.